Li Pang1, Da-Wei Wang1, Nan Zhang1, Da-Hai Xu1, Xiang-Wei Meng2. 1. Department of Emergency, The First Hospital of Jilin University, Changchun, Jilin, China. 2. Department of Gastrointestinal Medicine, The First Hospital of Jilin University, Changchun, Jilin, China.
Abstract
BACKGROUND: Matrix metalloproteinase 11 (MMP11) has been shown to play a key role in human tumor progression and indicates poor clinical outcome in cancer patients. OBJECTIVE: The current study aimed to evaluate the relationship between serum levels of MMP-11 and prognosis in colon cancer patients. METHODS: Serum levels of MMP-11 were determined in 92 colon cancer patients and 92 healthy individuals using an enzyme-linked immunosorbent assay (ELISA). Associations between serum MMP-11 levels and clinicopathological characteristics of the patients and their outcomes were investigated. Survival analyses were performed to measure the 5-year overall survival (OS) and disease-free survival (DFS). RESULTS: Serum MMP-11 levels were substantially higher in colon cancer patients than in healthy controls. Moreover, serum MMP-11 levels were significantly higher in patients with advanced T status, lymph node metastasis, distant metastasis, and a higher TNM stage. Elevated serum levels of MMP-11 were identified as an independent prognostic factor for 5-year mortality and adverse events associated with colon cancer. Multivariate Cox regression analysis identified the serum MMP-11 level as an independent predictor of OS and DFS. CONCLUSION: Our study established that high serum levels of MMP-11 are associated with poor clinical outcome and may serve as a prognostic biomarker in colon cancer patients.
BACKGROUND:Matrix metalloproteinase 11 (MMP11) has been shown to play a key role in humantumor progression and indicates poor clinical outcome in cancerpatients. OBJECTIVE: The current study aimed to evaluate the relationship between serum levels of MMP-11 and prognosis in colon cancerpatients. METHODS: Serum levels of MMP-11 were determined in 92 colon cancerpatients and 92 healthy individuals using an enzyme-linked immunosorbent assay (ELISA). Associations between serum MMP-11 levels and clinicopathological characteristics of the patients and their outcomes were investigated. Survival analyses were performed to measure the 5-year overall survival (OS) and disease-free survival (DFS). RESULTS: Serum MMP-11 levels were substantially higher in colon cancerpatients than in healthy controls. Moreover, serum MMP-11 levels were significantly higher in patients with advanced T status, lymph node metastasis, distant metastasis, and a higher TNM stage. Elevated serum levels of MMP-11 were identified as an independent prognostic factor for 5-year mortality and adverse events associated with colon cancer. Multivariate Cox regression analysis identified the serum MMP-11 level as an independent predictor of OS and DFS. CONCLUSION: Our study established that high serum levels of MMP-11 are associated with poor clinical outcome and may serve as a prognostic biomarker in colon cancerpatients.
Authors: Aline Simoneti Fonseca; Anelisa Ramão; Matheus Carvalho Bürger; Jorge Estefano Santana de Souza; Dalila Lucíola Zanette; Greice Andreotti de Molfetta; Luiza Ferreira de Araújo; Rafaela de Barros E Lima Bueno; Graziela Moura Aguiar; Jessica Rodrigues Plaça; Cleidson de Pádua Alves; Anemari Ramos Dinarte Dos Santos; Daniel Onofre Vidal; Gyl Eanes Barros Silva; Rodrigo Alexandre Panepucci; Fernanda Maris Peria; Omar Feres; José Joaquim Ribeiro da Rocha; Marco Antonio Zago; Wilson Araújo Silva Journal: BMC Cancer Date: 2021-03-01 Impact factor: 4.430